# Long Term Safety Study of Tanezumab in Chronic Low Back Pain

> **NCT00924664** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 849 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **BIOLOGICAL:** Tanezumab 20 mg
- **BIOLOGICAL:** Tanezumab 10 mg

## Key facts

- **NCT ID:** NCT00924664
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08-20
- **Primary completion:** 2010-11-30
- **Final completion:** 2011-06-22
- **Target enrollment:** 849 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924664, "Long Term Safety Study of Tanezumab in Chronic Low Back Pain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00924664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*